Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Frances R. Balkwill, Jermaine Coward et al.|Nature reviews. Cancer|2011Cited by 1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D.L. Bowtell, Frances R. Balkwill, Steffen Böhm et al.|Nature reviews. Cancer|2015Cited by 1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, James D. Brenton et al.|The Lancet|2019Cited by 223
HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian CancerEuan A. Stronach, Hani Gabra|Cancer Research|2011Cited by 179
LARP1 post-transcriptionally regulates mTOR and contributes to cancer progressionManuela Mura, Sarah P. Blagden, T.G. Hopkins et al.|Oncogene|2014Cited by 152